key: cord-0837151-dush0ae1
authors: Shi, Jinyun; Guo, Jia; Li, Zhidong; Xu, Baohui; Miyata, Masaaki
title: Importance of NLRP3 Inflammasome in Abdominal Aortic Aneurysms
date: 2021-05-01
journal: J Atheroscler Thromb
DOI: 10.5551/jat.rv17048
sha: bc1d2493b2d3bf173658cd2ddca366485cfdac6c
doc_id: 837151
cord_uid: dush0ae1

Abdominal aortic aneurysm (AAA) is a chronic inflammatory degenerative aortic disease, which particularly affects older people. Nucleotide-binding oligomerization domain-like receptor family protein 3 (NLRP3) inflammasome is a multi-protein complex and mediates inflammatory responses by activating caspase 1 for processing premature interleukin (IL)-1β and IL-18. In this review, we first summarize the principle of NLRP3 inflammasome activation and the functionally distinct classes of small molecule NLRP3 inflammasome inhibitors. Next, we provide a comprehensive literature review on the expression of NLRP3 inflammasome effector mediators (IL-1β and IL-18) and components (caspase 1, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) and NLRP3) in clinical and experimental AAAs. Finally, we discuss the influence of genetic deficiency or pharmacological inhibition of individual effector mediators and components of NLRP3 inflammasome on experimental AAAs. Accumulating clinical and experimental evidence suggests that NLRP3 inflammasome may be a promise therapeutic target for developing pharmacological strategies for clinical AAA management.

Abdominal aortic aneurysm (AAA) is a lifethreatening degenerative disease that is characterized by progressively localized dilatation of abdominal aorta, particularly infrarenal aorta. Advanced age, male sex, smoking, white race, hypertension, and hyperlipidemia increase the risk for AAAs, whereas female sex, black race, and diabetes reduce it [1] [2] [3] . There is a race difference in AAA prevalence, with high in Northern American and European and low in Asian 4, 5) . There is currently no effective pharmacological therapy available for AAAs, and patients are mainly treated with open or endovascular surgical repair as recommended by the Society for Vascular Surgery 6) and National Institute of Health and Care Excellence guideline for abdominal aortic aneurysm: diagnosis and management (https://www.nice.org.uk/ guidance/ ng156). Understanding of AAA pathogenesis will help establish nonsurgical pharmacological treatment for potassium efflux model, extracellular ATP activates purine-type membrane receptor P2X7, results in potassium efflux, and consequently reduces intracellular potassium levels, thus activating NLRP3 inflammasome 40) . Alternatively, certain crystalline or particulate matter enters cells and leads to lysosome rupture, which releases cathepsin B for NLRP3 inflammasome activation [41] [42] [43] . Interaction of mitochondria-derived reactive oxygen species (ROS) with thioredoxin-interacting protein is also able to trigger NLRP3 inflammasome activation. In addition, calcium influx also plays a role in NLRP3 inflammasome activation. All these mechanisms are not exclusive and may work together. For example, calcium influx results in mitochondrial ROS production, while lysosomal rupture promotes calcium influx 44, 45) .

Given the critical importance of NLRP3 inflammasome in a broad spectrum of inflammatory and degenerative diseases, to therapeutically target NLRP3 inflammasome, functionally distinct classes of NLRP3 inhibitors have been discovered. This has been the subject of several outstanding recent review articles 34, [46] [47] [48] [49] . NLRP3 inflammasome inhibitors target either signal 1 or signal 2. As one of signal 1 inhibitors, Bay 11-7082 inhibits transcription of IL-1 and IL-18 by blocking IKKb kinase and NF-kB signaling pathway 47, 50) . JC124 suppresses the expression of IL-1 , NLRP3, ASC, and caspase 1 51) . molecular patterns or damage-associated molecular patterns, it activates caspase 1 for processing inactive interleukin (IL)-1 or IL-18 to its active form for innate immune response. NLRP3 inflammasome has been known to participate in many pathological conditions including cardiovascular diseases [36] [37] [38] [39] .

NLRP3 inflammasome is one of the wellcharacterized inflammasomes, with three major components: NLRP3 receptor protein, ASC adapter protein, and caspase 1 effector protein ( Fig. 1) 34, 35) . NLRP3 protein contains one leucine-rich repeat for ligand recognition, one nucleotide-binding oligomerization domain with ATPase activity for nucleic acid binding and self-oligomerization, and one pyrin domain for ASC binding. ASC protein composes of one pyrin domain and one caspase recruitment domain. Once NLRP3 inflammasome is activated, ASC binds to NLRP3 protein through the pyrin domain for recruiting and activating caspase 1 via caspase recruitment domain.

There are two signals required for NLRP3 inflammasome activation 34, 35) (Fig. 2) : Signal 1 (priming) activates NF-B pathway through toll-like receptors, leading to the mRNA expression of IL-1 , IL-18, and NLRP3-related genes, and signal 2 (activation) such as damage-and pathogen-associated molecular patterns assembles NLRP3 inflammasome and activates caspase 1. Several potential mechanisms have been proposed for NLRP3 activation. In NLRP3 inflammasome is a protein complex composing of ASC (apoptosis-associated speck-like protein containing a caspase recruitment domain), pro-caspase-1, and NLRP3 protein. NLRP3 protein recruits ASC through the interaction of N-terminal PYD-PYD. ASC connects NLRP3 protein with pro-caspase-1 through PYD-PYD and CARD-CARD to form a pro-caspase-1 tetramer, which provides caspase 1 with enzyme cutting activity. LRR, leucine-rich repeat. NACHT/NOD, nucleotide-binding oligomerization domain.

NLRP3 with other complex components. For example, MCC950, CY-09, OLT1177/dapansutrile, MNS, and parthenolide inhibit NLRP3 by inhibiting its ATPase activity or modifying its ATPase domain 38, 48, [54] [55] [56] [57] . Blocking NLRP3-MEK7 by oridonin via binding to NLRP3 cysteine 279 or NLRP3 oligomerization by tranilast specifically inhibits NLRP3 inflammasome 58) . Glyburide also inhibits NLRP3 inflammasome by inhibiting ATP-sensitive potassium channel and thus disturbs ASC aggregation 59) . Resveratrol inhibits the assembly of ASC and NLRP3 60) . Targeting molecules that interact with either NLRP3 or ACS represent alternative approaches for alternative inhibitor discovery 48) .

Additional avenues for targeting inhibition of NLRP3 inflammasome activity are to specifically inhibit its effector mediators. These include IL-1 , IL-18, their receptors, or receptor antagonist as represented by two humanized anti-IL-1 monoclonal antibodies (canakinumab and gevokizumab) and two IL-1 receptor antagonists (anakinra and rilonacept) 36, 37) .

Among NLRP3 inflammasome inhibitors, some are currently used for treating certain medical Most inhibitors have however been designed to target signal 2, including upstream inducers (ion fluxes, mitochondrial ROS, nondegradable particles, and lysosomal proteinase cathepsin B), NLRP3 complex components (ASC and caspase 1), and NLRP3 per se 47, 48) . -hydroxybutyrate inhibits NLRP3 inflammasome by blocking potassium efflux 52, 53) , whereas both 5-nitro-2-(3-phenylpropylamino) b e n z o i c a c i d , 4 , 4 ' -d i i s o t h i o c y a n o -2 , 2 'disbenedisufonic acid, and IAA94 inhibit NLRP3 by disrupting chloride efflux 48) . Blockage of calcium mobilization by 2-APB, XeC, and U73122, the reduction of mitochondrial ROS by N-acetyl-Lcysteine and (2R,4R)-4-aminopyrro lidine-2,4dicarboxylate, and the prevention of lysosomal rupture by a specific inhibitor to cathepsin, CA-074-Me, all inhibit NLRP3 inflammasome 48) . Inhibition of caspase 1 by VX-740 and VX-756 or the conversion of procaspase-1 to active caspase 1 by FC11A-2 also results in the inhibition of NLRP3 inflammasome 47, 48) .

More important and specific inhibitors to NLRP3 inflammasome are those that directly inhibit NLRP3 activity, oligomerization, or interaction of Signal 2: DAMP (damage-associated molecular patterns) and PAMPs (pathogen-associated molecular patterns) are recognized by NLRP3, causing NLRP3-ASC-pro-caspase-1 inflammasome assembly and activation, which convert inactive caspase 1 to active caspase 1 and subsequently cleaves pro-IL-18 or pro-IL-1 to corresponding active form.

IL-18 mRNA and protein abundance have been shown in AAAs induced by combined use of Ang II and -aminopropionitrile 79) . In summary, both clinical and experimental data support elevated levels of NLRP3 inflammasome effector mediators in AAA disease.

ASC, caspase 1, and NLRP3 are key elements in NLRP3 inflammasome complex. Analysis of 100 patients with vascular diseases, including 34 AAA patients, revealed high mRNA expression levels of ASC, caspase 1, and NLRP3 in peripheral mononuclear cells from male patients as compared to female patients; it was however unknown whether this difference was associated with increased risk for AAAs in males 68) . The mRNA levels for caspase 1 and NLRP3 were higher in male AAA patients than those in non-AAA patients, but reduced protein levels were only noted for NLRP3 68) . In another study, both NLRP3 and ASC protein levels, as assessed by flow cytometric analysis, were higher in circulating granulocytes and monocytes in AAA patients than those in non-AAA controls, but the differences did not reach statistical significance 80) .

In aneurysmal aortae, an early study by Schonbeck et al. showed increased aortic protein levels of caspase 1 in AAA patients as compared to non-AAA patient controls. NLRP3 mRNA levels were increased in the aortae of aneurysmal patients as compared to occlusive aortic disease and healthy controls 81) . In another study analyzing aortae from 46 aneurysmal patients and 40 healthy organ donors 82) , more NLRP3-positive staining was noted in the aortae from aneurysmal patients as compared to non-AAA patient controls, with no difference in ASC and caspase 1 staining between two patient groups. However, NLRP3 expression levels were inversely associated with inflammation pathological grade, implying that NLRP3 inflammasome may be an early event in AAA pathogenesis 82) . In addition, smooth muscle cells from AAA patients had an increased ability to express NLRP3 and caspase 1 in response to necrotic cell debris 83) .

In contrast, studies on the expression of NLRP3 inflammasome components are limited for experimental AAAs. In Ang II-induced AAAs, ASC was highly expressed in adventitial macrophages 74) . Increased active caspase 1 was also elevated in Ang II-induced aneurysmal aorta 84) . Furthermore, NLRP3 and active caspase 1 were also detected in aneurysmal aorta in calcium chloride AAA model and further augmented by hyperhomocysteinemia 78) . Although conditions with proved safety. For example, glyburide and its analogs are used to treat type 2 diabetes, while tranilast is an approved drug for treating allergic diseases in China, Korea, and Japan. Resveratrol is commercially available as a nutritional supplement. A large number of clinical trials have been registered to test the safety and efficacy of functionally distinct classes of NLRP3 inflammasome inhibitors for various inflammatory diseases through https://clinicaltrials. gov or alternative clinical organizations. In one openlabel, dose-adaptive, proof-of-concept phase II trial, dapansutrile has been shown to safely and effectively reduce joint pain in patients with goat flare 61) . In another trial, dapansutrile will be tested for treatment of moderate COVID-19 symptoms and early cytokine syndrome (https://clinicaltrials.gov). Several clinical trials have also completed or are undergoing to test the therapeutic efficacy of canakinumab, gevokizumab, anakinra, and rilonacept for treating several cardiovascular diseases such as certain type of heart failure and acute myocardial infraction 36) .

In clinical AAAs, it has been reported that serum IL-1 levels were elevated in AAA patients as compared to healthy controls and patients with coronary heart disease 62) . High plasma levels of IL-1 were observed in participants who had homozygous for common C allele of NLRP3 rs35829419 but not polymorphisms of any IL-1 gene cluster 63, 64) . However, Batra et al. reported detectable levels of serum IL-1 in non-aneurysmal patients, but not aneurysmal patients. In aortic tissues from aneurysmal patients, most studies have shown that IL-1 mRNA and protein levels were higher in aneurysmal patients than those in non-aneurysmal patients [65] [66] [67] [68] [69] [70] [71] . The mRNA and protein levels of IL-18, another NLRP3 inflammasome effector mediator, were also increased in the aortae of patients with AAAs as compared to non-aneurysmal controls 72, 73) .

Consistent with the findings in clinical AAAs, IL-1 mRNA and protein levels were markedly increased in aneurysmal mice created by intra-aortic elastase infusion or adventitial calcium painting in normolipidemic mice, subcutaneous Ang II infusion, or alternative technique 65, [74] [75] [76] [77] . Elevated aortic IL-1 protein levels were also noted in hyperhomocysteinemia-accelerated experimental AAAs 78) . Both aortic macrophages and smooth muscle cells have been identified as major sources for increased expression of IL-1 74, 78) . IL-1 levels were also significantly higher in aneurysmal mice than those in non-aneurysmal mice in Ang II-induced AAAs 74) . In addition, increased aortic acid-binding protein 4. Together, accumulating evidence from recently published studies supports the importance of both mediators in AAA disease using various AAA modeling systems.

Two studies, however, have failed to demonstrate the contribution of IL-1 to experimental AAAs. In an early study, treatment with anti-IL-1 receptor antagonist was not effective in suppressing elastaseinduced AAAs in rats 86) . In experimental AAAs created by topical application of calcium chloride, deficiency of IL-1 or IL-1 receptor had no remarkable impact on AAA formation, although it decreased MMP expression levels 75) .

Processing pro-IL-1 and pro-IL-18 to their active forms can also be mediated by other inflammasomes rather than NLRP3. As shown in Table 2 , mice with genetic deficiency of individual NLRP3 inflammasome components have contributed to our understanding of NLRP3 inflammasome in AAA pathogenesis. In Ang II infusion/ApoE-deficient AAA model, whole-body ablation of NLRP3, ASC, or caspase 1 reduced aneurysm incidence, attenuated aneurysmal aortic enlargement, and preserved medial elastin and smooth muscle cells 74) . Similarly, AAA suppression has also been confirmed in high fat diet fed NLRP3-or caspase 1-deficient mice following chronic Ang II infusion 87) . In Kawasaki diseaseassociated AAAs, deficiency of NLRP3 or caspase 1 also led to AAA suppression 77) . In addition, topical application of lentivirus siRNA to aortic wall abrogated AAAs in alternative calcium AAA model 78) . Altogether, these genetic studies provide solid evidence for NLRP3 inflammasome in AAA pathogenesis. Table 3 summarizes published studies on the influence of various NLRP3 inflammasome inhibitors on experimental AAAs. Yamanouchi D et al. have shown that treatment with Q-Vd-OPh, a pan-caspase inhibitor, inhibited Ang II infusion-induced aneurysmal aortic enlargement and reduced AAA incidence in ApoE-deficient mice. The AAA suppression was accompanied by attenuation of aortic macrophage infiltration, smooth muscle cell apoptosis, and CCL2-mediated macrophage migration 88) . Administration of tranilast has been shown to suppress calcium chloride-induced AAAs in association with preservation of medial elastin, attenuation of mural mast cells and lymphocytes, reduced neoangiogenesis, and reduced MMP9 activity 89) . Treatment with evidence from experimental AAAs is limited, a large body of evidence from clinical AAA studies has demonstrated increased expression of NLRP3 inflammasome components in aneurysmal lesion or immune cells.

Several studies have been conducted to investigate the role of two NLRP3 inflammasome effector cytokines, IL-1 and IL-18, in AAA pathogenesis using rodents deficient for IL-1 , IL-18 or its cognate receptor, or pharmacological inhibitors ( Table 1 ). In mice deficient for IL-1 or IL-1 receptor, or treated with IL-1 receptor blocker anakinra, Johnston et al. reported attenuation of aneurysmal aortic enlargement and accumulation of macrophages and neutrophils following intra-aortic elastase infusion 65) . In these experimental settings, AAA suppression was associated with reduced expression levels or activity of CC-motif chemokine ligand 2, IL-6, complement C5a, and matrix metalloproteinase (MMP) 9. A recent study by Meker et al. reported that IL-1 mediated AAA disease by promoting neutrophil extracellular trap formation 69) . In a special form of AAAs associated with Kawasaki disease induced by Lactobacillus casei cell wall extract injection, AAAs were suppressed in mice deficient for IL-1 , IL-1 , or IL-1 receptor or treated with an antibody against IL-1 , IL-1 , or IL-1 receptor 77) . Conversely, Ang II-induced AAAs were accelerated in high fat diet fed mice deficient for IL-1 receptor antagonist and counteracted following IL-1 antibody injection 85) .

Two recent studies have further demonstrated the significance of IL-18 in experimental AAAs. In Ang II/ -aminopropionitrile (lysyl oxidase inhibitor)induced AAA model 79) , genetic deficiency of IL-18 suppressed aneurysmal aortic expansion and lowered AAA incidence in association with reduced aortic CD68-positive macrophage infiltration, pro-and active MMP levels, and osteopontin. IL-18 deficiency also resulted in a switch from proinflammatory M1 macrophage activation toward anti-inflammatory M2 macrophage activation as indicated by reduced ratio of CD11c-positive to CD206-positive macrophages in aneurysmal aorta. Similarly, deficiency of either receptor for IL-18, IL-18 receptor or Na-Cl cotransporter, also suppressed Ang II-induced AAAs in ApoE-deficient hyperlipidemic mice as evidenced by reduced aortic diameter expansion and active MMP2 and MMP9 73) . In these experimental settings, adipocytes have been shown to promote IL-18 function by inducing the expression of leptin and fatty formation induced by Ang II 87) , potentially associated with AAA inhibition in diabetic patients [90] [91] [92] . Treatment with glucagon-like peptide receptor agonist suppressed elastase infusion-induced AAAs in rats by reducing ROS production and aortic inflammatory response 93) . Sitagliptin, a dipeptidyl peptidase-4 MCC950 also inhibited the development of aortic aneurysms at various aortic segments, including abdominal aorta, in conjunction with reduced expression levels of NLRP3, caspase 1, and MMPs and preserved contractible proteins of smooth muscle cells 84) . Treatment with glyburide also reduced AAA work.

This work was in part supported by grants from the National Natural Science Foundation of China (grant number 81600256), the Natural Science inhibitor, prevented the formation and progression of AAAs by increasing glucagon-like peptide [94] [95] [96] [97] . Resveratrol has also been reported to suppress AAA formation in Ang II, elastase, and/or calcium models [98] [99] [100] . All published studies were to evaluate the preventive effect of pharmacological NLRP3 inhibitor on AAAs by administering inhibitors prior to AAA induction. It has not been investigated whether NLRP3 inhibition is effective in limiting the progression of existing small experimental AAAs, which is more clinically relevant. In addition, most studies have also been performed in Ang II-induced AAAs in hyperlipidemic animals, which is primarily initiated and driven by aortic dissection. Thus, it warrants more validating studies in non-dissection AAA models such as intra-aortic elastase infusion model or alternatives.

In summary, clinical and experimental evidence supports the critical importance of NLRP3 inflammasome in AAA pathogenesis. Thus, pharmacologically targeting NLRP3 inflammasome activity may provide a novel translational application for clinically treating small AAA disease.

All authors declare no conflicts of interest to this 

Efficacy and mechanism of angiotensin II receptor blocker treatment in experimental abdominal aortic aneurysms

Inhibition or deletion of angiotensin II type 1 receptor suppresses elastaseinduced experimental abdominal aortic aneurysms

Pathogenic and Therapeutic Significance of Angiotensin II Type I Receptor in Abdominal Aortic Aneurysms

Angiotensin-converting enzyme 2 decreases formation and severity of angiotensin II-induced abdominal aortic aneurysms

Bone marrow transplantation reveals that recipient AT1a receptors are required to initiate angiotensin II-induced atherosclerosis and aneurysms

Oxidative stress and abdominal aortic aneurysm: potential treatment targets

Smooth muscle cell-specific Tgfbr1 deficiency promotes aortic aneurysm formation by stimulating multiple signaling events

TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice

Smooth Muscle Cell Reprogramming in Aortic Aneurysms

Chemokine (C-C motif ) receptor 2 mediates mast cell migration to abdominal aortic aneurysm lesions in mice

Bone marrow-derived monocyte chemoattractant protein-1 receptor CCR2 is critical in angiotensin II-induced acceleration of atherosclerosis and aneurysm formation in hypercholesterolemic mice

Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group

Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals

Sex-Specific Associations of Vascular Risk Factors With Abdominal Aortic Aneurysm: Findings From

Million Women and 0.8 Million Men in the United States and United Kingdom

Prevalence and trends of the abdominal aortic aneurysms epidemic in general population--a meta-analysis

Systematic review and meta-analysis of the prevalence of abdominal aortic aneurysm in Asian populations

The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm

CD95-ligand contributes to abdominal aortic aneurysm progression by modulating inflammation

Decreased vascular smooth muscle cell density in medial degeneration of human abdominal aortic aneurysms

Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms

Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms

Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model

Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease

Interleukin-1 function and role in rheumatic disease

A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases

Role of NLRP3 Inflammasomes in Atherosclerosis

Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration

Cell Volume Regulation Modulates NLRP3 Inflammasome Activation

The NALP3 inflammasome is involved in the innate immune response to amyloidbeta

Cholesterol-dependent cytolysins induce rapid release of mature IL-1beta from murine macrophages in a NLRP3 inflammasome and cathepsin B-dependent manner

TRPM2 links oxidative stress to NLRP3 inflammasome activation

Critical role for calcium mobilization in activation of the NLRP3 inflammasome

Targeting the NLRP3 inflammasome in inflammatory diseases

Pharmacological Inhibitors of the NLRP3 Inflammasome

The strategies of targeting the NLRP3 inflammasome to treat inflammatory diseases

Development of covalent NLRP3 inflammasome inhibitors: Chemistry and biological activity

formation, MKEY, inhibits experimental aortic aneurysm initiation and progression

Hypoxia-inducible factor 1 in clinical and experimental aortic aneurysm disease

Vascular endothelial growth factor enhances angiotensin II-induced aneurysm formation in apolipoprotein E-deficient mice

Rapamycin limits the growth of established experimental abdominal aortic aneurysms

Role of vascular endothelial growth factor-A in development of abdominal aortic aneurysm

Inhibition of VEGF (Vascular Endothelial Growth Factor)-A or its Receptor Activity Suppresses Experimental Aneurysm Progression in the Aortic Elastase Infusion Model

Analysis of in situ and ex vivo vascular endothelial growth factor receptor expression during experimental aortic aneurysm progression

Hemodynamic regulation of CD34+ cell localization and differentiation in experimental aneurysms

Wall shear stress and strain modulate experimental aneurysm cellularity

Hemodynamic forces regulate mural macrophage infiltration in experimental aortic aneurysms

Enhanced abdominal aortic aneurysm formation in thrombin-activatable procarboxypeptidase B-deficient mice

The NLRP3 inflammasome: molecular activation and regulation to therapeutics

Joosten LAB: Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial

Elevated circulating levels of inflammatory cytokines in patients with abdominal aortic aneurysm

Interaction of the inflammasome genes CARD8 and NLRP3 in abdominal aortic aneurysms

Interleukin-1 gene cluster variants and abdominal aortic aneurysms

Genetic and pharmacologic disruption of interleukin-1 signaling inhibits experimental aortic aneurysm formation

Cytokines that activate proteolysis are increased in abdominal aortic aneurysms

Abdominal aortic aneurysm and aortic occlusive disease: a comparison of risk factors and inflammatory response

Sex-and disease-specific inflammasome signatures in circulating blood leukocytes of patients with abdominal aortic aneurysm

Novel Role of IL (Interleukin)-1 in Neutrophil Extracellular Trap Formation and Abdominal Aortic Aneurysms

The influence of indomethacin on the metabolism and cytokine secretion of human aneurysmal aorta

Interleukin-1 beta and tumor necrosis factor-alpha release in normal and diseased human infrarenal aortas

T(H)2 predominant immune responses prevail in human abdominal aortic aneurysm

Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome

Structural Insights of Benzenesulfonamide Analogues as NLRP3 Inflammasome Inhibitors: Design, Synthesis, and Biological Characterization

The ketone metabolite -hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease

Hydroxybutyrate Deactivates Neutrophil NLRP3 Inflammasome to Relieve Gout Flares

MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition

MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition

Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders

OLT1177, a -sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation

Oridonin is a covalent NLRP3 inhibitor with strong antiinflammasome activity

Glyburide inhibits the Cryopyrin/Nalp3 inflammasome

Resveratrol inhibits the acetylated -tubulinmediated assembly of the NLRP3-inflammasome

Targeting the NLRP3

Inflammasome With Inhibitor MCC950 Prevents Aortic Aneurysms and Dissections in Mice

Inhibition of interleukin-1 suppresses angiotensin II-induced aortic inflammation and aneurysm formation

Interleukin-1 beta induces differential gene expression in aortic smooth muscle cells

NLRP3 (Nucleotide Oligomerization Domain-Like Receptor Family, Pyrin Domain Containing 3)-Caspase-1 Inflammasome Degrades Contractile Proteins: Implications for Aortic Biomechanical Dysfunction and Aneurysm and Dissection Formation

Effects of caspase inhibitor on angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice

Adventitial mast cells contribute to pathogenesis in the progression of abdominal aortic aneurysm

Metformin treatment status and abdominal aortic aneurysm disease progression

Association between use of oral-antidiabetic drugs and the risk of aortic aneurysm: a nested case-control analysis

Metformin prescription status and abdominal aortic aneurysm disease progression in the U.S. veteran population

Glucagon-like peptide-1 prevented abdominal aortic aneurysm development in rats

Dipeptidyl peptidase-4 inhibitor decreases abdominal aortic aneurysm formation through GLP-1-dependent monocytic activity in mice

Shih CC: A potential contribution of dipeptidyl peptidase-4 by the mediation of monocyte differentiation in the development and progression of binding to its receptors during abdominal aortic aneurysm formation in mice

Inflammasome activation by mitochondrial oxidative stress in macrophages leads to the development of angiotensin II-induced aortic aneurysm

IL-1 (Interleukin-1 ) and TNF-(Tumor Necrosis Factor-) Impact Abdominal Aortic Aneurysm Formation by Differential Effects on Macrophage Polarization

Temporal changes in mouse aortic wall gene expression during the development of elastase-induced abdominal aortic aneurysms

Role of Interleukin-1 Signaling in a Mouse Model of Kawasaki Disease-Associated Abdominal Aortic Aneurysm

Macrophage inflammasome mediates hyperhomocysteinemiaaggravated abdominal aortic aneurysm

Deletion of interleukin-18 attenuates abdominal aortic aneurysm formation

AIM2 levels and DNAtriggered inflammasome response are increased in peripheral leukocytes of patients with abdominal aortic aneurysm

Differential mRNA expression of inflammasome genes NLRP1 and NLRP3 in abdominal aneurysmal and occlusive aortic disease

Inflammasome activity in leucocytes decreases with abdominal aortic aneurysm progression

Necrotic cell debris induces a NF-B-driven inflammasome response in vascular smooth muscle cells derived from abdominal aortic aneurysms (AAA-SMC)

Aneurysm Associated With Upregulation of Angiotensin-Converting Enzyme 2

Resveratrol prevents the development of abdominal aortic aneurysm through attenuation of inflammation, oxidative stress, and neovascularization

Resveratrol Counteracts Systemic and Local Inflammation Involved in Early Abdominal Aortic Aneurysm Development

A Dipeptidyl Peptidase-4 Inhibitor but not Incretins Suppresses Abdominal Aortic Aneurysms in Angiotensin II-Infused Apolipoprotein E-Null Mice

Suppression of Abdominal Aortic Aneurysm Formation in Mice by Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor